Literature DB >> 31335165

Practical Application of Real-World Evidence in Developing Cancer Therapies.

Marjorie G Zauderer1.   

Abstract

Entities:  

Year:  2019        PMID: 31335165      PMCID: PMC6873932          DOI: 10.1200/CCI.19.00071

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


× No keyword cloud information.
  14 in total

1.  Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.

Authors:  Jacqueline Corrigan-Curay; Leonard Sacks; Janet Woodcock
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

2.  Pembrolizumab plus Chemotherapy in Lung Cancer.

Authors:  Leena Gandhi; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-09-13       Impact factor: 91.245

3.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

4.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.

Authors:  Kathryn C Arbour; Laura Mezquita; Niamh Long; Hira Rizvi; Edouard Auclin; Andy Ni; Gala Martínez-Bernal; Roberto Ferrara; W Victoria Lai; Lizza E L Hendriks; Joshua K Sabari; Caroline Caramella; Andrew J Plodkowski; Darragh Halpenny; Jamie E Chaft; David Planchard; Gregory J Riely; Benjamin Besse; Matthew D Hellmann
Journal:  J Clin Oncol       Date:  2018-08-20       Impact factor: 44.544

5.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

6.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

7.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Authors:  Louis Fehrenbacher; Alexander Spira; Marcus Ballinger; Marcin Kowanetz; Johan Vansteenkiste; Julien Mazieres; Keunchil Park; David Smith; Angel Artal-Cortes; Conrad Lewanski; Fadi Braiteh; Daniel Waterkamp; Pei He; Wei Zou; Daniel S Chen; Jing Yi; Alan Sandler; Achim Rittmeyer
Journal:  Lancet       Date:  2016-03-10       Impact factor: 79.321

8.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

9.  An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Authors:  Mark Stewart; Andrew D Norden; Nancy Dreyer; Henry Joe Henk; Amy P Abernethy; Elizabeth Chrischilles; Lawrence Kushi; Aaron S Mansfield; Sean Khozin; Elad Sharon; Srikesh Arunajadai; Ryan Carnahan; Jennifer B Christian; Rebecca A Miksad; Lori C Sakoda; Aracelis Z Torres; Emily Valice; Jeff Allen
Journal:  JCO Clin Cancer Inform       Date:  2019-07

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

View more
  3 in total

1.  Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.

Authors:  Khava I E Ibragimova; Sandra M E Geurts; Sander Croes; Frans Erdkamp; Joan B Heijns; Jolien Tol; Birgit E P J Vriens; Kirsten N A Aaldering; Marcus W Dercksen; Manon J A E Pepels; Natascha A J B Peters; Linda van de Winkel; Dominique J P Tilli; Ingeborg J H Vriens; Maaike de Boer; Vivianne C G Tjan-Heijnen
Journal:  Breast Cancer Res Treat       Date:  2021-03-20       Impact factor: 4.872

2.  Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer.

Authors:  Yue Li; Chong Li; Ya Jiang; Xue Han; Sisi Liu; Xiuxiu Xu; Wanxiangfu Tang; Qiuxiang Ou; Hua Bao; Xue Wu; Yang Shao; Minyan Xing; Yixiang Zhang; Yuezhen Wang
Journal:  J Oncol       Date:  2022-04-11       Impact factor: 4.501

3.  Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study.

Authors:  Jean-Baptiste Assié; Florian Crépin; Emmanuel Grolleau; Anthony Canellas; Margaux Geier; Aude Grébert-Manuardi; Nabila Akkache; Aldo Renault; Pierre-Alexandre Hauss; Marielle Sabatini; Valentine Bonnefoy; Alexis Cortot; Marie Wislez; Clément Gauvain; Christos Chouaïd; Arnaud Scherpereel; Isabelle Monnet
Journal:  Cancers (Basel)       Date:  2022-03-15       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.